Press Releases
SALT LAKE CITY, Sept. 28, 2019 /PRNewswire/ -- Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today presented new data from the ongoing Phase 1 study evaluating the maximum tolerated dose (MTD) of the oral investigational agent TP-0903, an AXL receptor tyrosine kinase (RTK) inhib
Read more...FRAMINGHAM, Mass., Sept. 28, 2019 /PRNewswire/ -- BERG, a clinical stage biopharmaceutical company that utilizes artificial intelligence (AI) and multi-omics to identify novel biology and disease modifying targets, today announced results from a predictive analysis of adverse events by the BERG platform, for a multi-center Phase 1 study evaluating BPM31510 (novel ubideca
Read more...WHIPPANY, N.J., Sept. 28, 2019 /PRNewswire/ -- Updated clinical data for Vitrakvi® (larotrectinib) in adult and pediatric patients with TRK fusion cancer demonstrated an overall response rate (ORR) of 79 percent (n=121; 95% CI, 72–85), including 16 percent complete responses (CR) and 63 percent partial responses (PR) per investigator assessment.
Read more...LONDON, Sept. 28, 2019 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced GSK3359609, an inducible T cell co-stimulatory (ICOS) agonist antibody designed to selectively enhance T cell function, showed promising anti-tumour activity in combination with pembrolizumab in PD-1/L1 naive patients with head and neck squamous cell carcino
Read more...BOTHELL, Wash. and TOKYO, Sept. 28, 2019 /PRNewswire/ --
Read more...28 September 2019
THOUSAND OAKS, Calif., Sept. 27, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutant solid tumors. The data include the first evidence of anti-tumor activity reported in patients with colorectal cancer (CRC) and appendiceal cancer, as well as
Read more...27 September 2019
SHANGHAI and NEW YORK, Sept. 27, 2019 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that a drug application* for its off-the-shelf autologous adip
Read more...NEW YORK, Sept. 27, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating the proposed merger of Avedro, Inc. ("Avedro" or the "Company") (NASDAQ: AVDR) with Glaukos Corporation ("Glaukos").
Read more...MONMOUTH BEACH, N.J., Sept. 27, 2019 /PRNewswire/ -- RH Nanopharmaceuticals,LLC is pleased to announce that it has been awarded the National Institute of Health – H
Read more...27 September 2019
NASHVILLE, Tenn., Sept. 27, 2019 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) ("Brookdale" or the "Company") today announced that it has entered into a support agreement with Glenview Capital Management ("Glenview"), the Company's largest stockholder. Glenview owned approximately 9.9% of the Company's outstanding common stock as of the close of business on
Read more...